Tesaro

Activities: Research & Development Pharmaceutical

Trending Articles

  1. Wacker Biotech to manufacture protein ingredients for MinervaX's late-stage GBS vaccine The vaccine is currently being prepared for Phase III trials, and aims to protect mothers and their babies from group B streptococcus infections
  2. Novartis' Kisqali plus ET bags FDA approval for HR+/HER2- breast cancer The decision comes off the back of the Phase III NATALEE clinical trial, which diminished the risk of disease recurrence by 25.1%
  3. AstraZeneca opens a 'people hub' at its Macclesfield site The energy-efficient building will offer AZ employees a collaborative space
  4. Ensuring cGMP compliance in cell and gene therapy manufacturing 3P discusses how companies can scale up their CGT manufacturing protocols while remaining compliant with stringent global regulations
  5. Piramal Pharma's sustainability goals get SBTi-validated The company wants to reduce its scope 1 and 2 GHG emissions by 42% by 2030, and is also working on developing a carbon reduction plan

Upcoming event

Boston Biotech Week

23-26 September, 2024 | Convention and exhibition | Boston, US See all

Related Content

Regulatory

STA signs 5 year supply agreement with TESARO

STA Pharmaceutical an open access capability and technology platform for small molecule pharmaceutical development and manufacturing — has signed a supply agreement with the oncology focused biopharmaceutical company, TESARO, for certain starting and intermediate materials for ZEJULA
Regulatory

Antiemetic – rolapitant

Antiemetic drugs are commonly given to reduce nausea and vomiting in cancer patients undergoing chemotherapy to improve their quality of life
Subscribe now